Javascript must be enabled to continue!
Structural‐equation‐modelling of the tropism impact on achieving viral suppression within six months in naïve HIV patients
View through CrossRef
IntroductionAim of the study was to evaluate the relevance of baseline (BL) plasma tropism of HIV on the achievement of a viral suppression within six months of antiviral therapy (ARV) in naïve patients by a structural‐equation‐modelling.Materials and MethodsTwo‐hundred and twenty‐seven patients were enrolled; viral tropism on plasma was determined at baseline (BL) by sequencing and interpretation by genotopheno algorithm. Booster atazanavir or lopinavir, or efavirenz or nevirapine were used, in combination with either abacavir/lamivudine or tenofovir‐emtricitabine.ResultsX4‐tropism correlate negatively with CD4 cell count at BL and follow‐up (FU), and CD4 correlate negatively with BL‐plasma viremia (PLV). BL‐PLV correlate positively with FU‐PLV. We have developed the hypothesis that the variables BL‐CD4 and BL‐PLV represent a mediators chain among X4‐tropism and outcome of plasma viraemia at six months. This model, after structural‐equation‐modelling (SEM, Stata13), is shown in Figure 1. The indirect effect of X4‐tropism on Fup‐PLV is significant (p<0.01) but about 10 fold lower than the direct effect by BL‐PLV. X4‐tropism also has a direct negative effect on BL‐CD4 (p<0.001) and an indirect positive effect on BL‐PLV (p<0.001), irrespective of the drug regimen. Path model explaining direct and mediated effects of “tro (tropism),” “gender,” “age,” “cd0 (BL‐CD4)” and “lrna0 (BL‐PLV)” on the final outcome (“lrna1‐Fup‐PLV),” where “tro,” “gender,” and “age” are exogenous, cd0 and lrna0 are endogenous (mediators). Numbers on the arrows indicate direct effects. Circles indicate residuals related to endogenous/dependent variables; numbers near to circles are the corresponding variances.ConclusionsThis model shows the relevance of BL‐tropism on the outcome of plasma viraemia in naïve patients after six months of therapy, irrespective of drug regimen used.
Title: Structural‐equation‐modelling of the tropism impact on achieving viral suppression within six months in naïve HIV patients
Description:
IntroductionAim of the study was to evaluate the relevance of baseline (BL) plasma tropism of HIV on the achievement of a viral suppression within six months of antiviral therapy (ARV) in naïve patients by a structural‐equation‐modelling.
Materials and MethodsTwo‐hundred and twenty‐seven patients were enrolled; viral tropism on plasma was determined at baseline (BL) by sequencing and interpretation by genotopheno algorithm.
Booster atazanavir or lopinavir, or efavirenz or nevirapine were used, in combination with either abacavir/lamivudine or tenofovir‐emtricitabine.
ResultsX4‐tropism correlate negatively with CD4 cell count at BL and follow‐up (FU), and CD4 correlate negatively with BL‐plasma viremia (PLV).
BL‐PLV correlate positively with FU‐PLV.
We have developed the hypothesis that the variables BL‐CD4 and BL‐PLV represent a mediators chain among X4‐tropism and outcome of plasma viraemia at six months.
This model, after structural‐equation‐modelling (SEM, Stata13), is shown in Figure 1.
The indirect effect of X4‐tropism on Fup‐PLV is significant (p<0.
01) but about 10 fold lower than the direct effect by BL‐PLV.
X4‐tropism also has a direct negative effect on BL‐CD4 (p<0.
001) and an indirect positive effect on BL‐PLV (p<0.
001), irrespective of the drug regimen.
Path model explaining direct and mediated effects of “tro (tropism),” “gender,” “age,” “cd0 (BL‐CD4)” and “lrna0 (BL‐PLV)” on the final outcome (“lrna1‐Fup‐PLV),” where “tro,” “gender,” and “age” are exogenous, cd0 and lrna0 are endogenous (mediators).
Numbers on the arrows indicate direct effects.
Circles indicate residuals related to endogenous/dependent variables; numbers near to circles are the corresponding variances.
ConclusionsThis model shows the relevance of BL‐tropism on the outcome of plasma viraemia in naïve patients after six months of therapy, irrespective of drug regimen used.
Related Results
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
HIV Viral Non-Suppression and Its Associated Factors Among PMTCT Mothers Receiving ARV Treatment in Ethiopia
HIV Viral Non-Suppression and Its Associated Factors Among PMTCT Mothers Receiving ARV Treatment in Ethiopia
AbstractBackgroundPediatric HIV infection is mainly caused by Mother-to-child transmission (MTCT). Without any effective medical intervention, 15-45% of infants born to HIV-positiv...
Faktor Prediktor Kegagalan Virologis pada Pasien HIV yang Mendapat Terapi ARV Lini Pertama dengan Kepatuhan Berobat Baik
Faktor Prediktor Kegagalan Virologis pada Pasien HIV yang Mendapat Terapi ARV Lini Pertama dengan Kepatuhan Berobat Baik
Pendahuluan. Pada negara dengan keterbatasan sumber daya, pengukuran viral load (VL) sebagai prediktor efektivitas terapi antiretroviral (ARV) tidak selalu mudah untuk diakses oleh...
CD4+ T cell count and HIV-1 viral load dynamics positively impacted by H. pylori infection in HIV-positive patients regardless of ART status in a high-burden setting
CD4+ T cell count and HIV-1 viral load dynamics positively impacted by H. pylori infection in HIV-positive patients regardless of ART status in a high-burden setting
Abstract
Background
There is a widespread co-infection of HIV and Helicobacter pylori (H. pylori) globally, particularly in developing countries, an...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

